Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking. METHODS: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety. RESULTS: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium. CONCLUSIONS: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid therapy [91].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [91]
In the citing paper
“In support of this notion, it is reported that anabolic agent, hPTH (1-34), is superior to bisphosphonates in increasing spine and hip BMD and reduces the incidence of new vertebral fractures in glucocorticoid-induced osteoporosis (GIOP) populations for both men and women [11, 47-49].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [11]
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Research works printed but not linked: 4
- 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K · DOI · Paper page
- Sambrook PN, 2001, Aust Fam Physician, 30, 793
- 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W · doi:10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w
- Mudano A, 2001, J Rheumatol, 28, 1298
Cited by
Items 601–700 of 910
Advances in the Treatment of Bone-Forming Drugs Contribute to Osteoporosis Diseases
张, 方. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.101013 · Cited by 5
Osteoporosis in Rheumatoid Arthritis
Geraci, A. (2012) · InTech eBooks · doi:10.5772/28677 · Cited by 4
Teriparatide: Its Use in the Treatment of Osteoporosis
Inderjeeth, C. A., Chan, K., & Glendenning, P. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s2358 · Cited by 4
Leitman, D., & Ross, K. (2009) · Cases Journal · doi:10.4076/1757-1626-2-7034 · Cited by 4
Dejaeger, E. W., Boonen, S., Coussement, J., & Milisen, K. (2009) · Tijdschrift voor Gerontologie en Geriatrie · doi:10.1007/bf03088520 · Cited by 4
Self-citationAxelrod, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00100-1 · Cited by 4
Glucocorticoid-induced osteoporosis
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2011) · doi:10.1093/med/9780199235292.003.0497 · Cited by 4
Teriparatide vs risedronate for osteoporosis – Authors' reply
Kendler, D. L., Geusens, P., Zerbini, C. A. F., Minisola, S., & Marín, F. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30756-6 · Cited by 4
Self-citationEmkey, G. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65820-8 · Cited by 4
Emkey, G. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00039-x · Cited by 4
Sambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012) · Bone · doi:10.1016/j.bone.2011.10.024 · Cited by 3
Self-citationHanda, H., Uzawa, A., Mori, M., Yasuda, M., Onishi, Y., Akamine, H., Ogaya, E., Niibe, Y., Yokota, H., & Kuwabara, S. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3954-24 · Cited by 3
EndoBridge 2024: pearls and highlights
Yıldız, B. O., Armeni, E., Balodimou, C., Biondi, B., Ciudin, A., Frühbeck, G., Fuleihan, G. E., Geer, E. B., Gillard, P., Gordon, C. M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00708-5 · Cited by 4
Multilevel text mining for bone biology
Tilak, O. J., Hoblitzell, A., Mukhopadhyay, S., You, Q., Fang, S., Xia, Y., & Bidwell, J. P. (2011) · Concurrency and Computation Practice and Experience · doi:10.1002/cpe.1788 · Cited by 3
Strontium ranelate: an effective solution for diverse fracture risks
Ringe, J. D. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1241-2 · Cited by 6
Current Medical Therapies for Osteoporosis and Its Alternative Treatments Using Natural Products
Oh, S., & Ahn, S. (2015) · Journal of Life Science · doi:10.5352/jls.2015.25.1.113 · Cited by 3
Martin, C. T., Niewoehner, C. B., & Burmeister, L. A. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00049 · Cited by 3
Role of Parathyroid Hormone in Regulating Transporter and Metabolizing Enzyme Function
Watanabe, H., & Maruyama, T. (2018) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12686 · Cited by 3
Wang, D., & Wang, H. (2022) · Physiology · doi:10.5772/intechopen.101803 · Cited by 6
Osteoporosis in Premenopausal Women
Cohen, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00045-5 · Cited by 4
Multidisciplinary Management of Menopause: Symposium Proceedings
Kornstein, S. G., Pinkerton, J. V., Pace, D. T., Singer, A. J., Kingsberg, S. A., Ellis, L. E., Ashley, P., & Klein, W. (2022) · Journal of Women s Health · doi:10.1089/jwh.2022.0175 · Cited by 3
Coco-Martín, M. B., Vega, L. L., Blázquez-Cabrera, J. A., Navarro, A., Moro, M. J., Arranz-García, F., Amérigo, M. J., Henríquez, M. S., Vázquez, M. Á., Montoya-García, M.-J., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03544-x · Cited by 3
An Overlooked Medication-Induced Celiac Flare Complicating Treatment of Osteoporosis
Phan, V., Aurora, J. A., Gondi, S., & Ceglia, L. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.01.001 · Cited by 3
Zhao, A. S., Liu, Y., Mulvey, J. J., & Tchang, B. G. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07243-w · Cited by 3
Guyer, L., Lehmann, O., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Schmid, G., Häuselmann, H., Reichenbach, S., et al. (2025) · Bone · doi:10.1016/j.bone.2025.117445 · Cited by 3
Marcelli, C. (2011) · EMC - Appareil locomoteur · doi:10.1016/s0246-0521(11)51769-3 · Cited by 3
Cooper, M. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03494.x · Cited by 3
Osteoporosis and Bone Health in Patients with Lung Disease
Bolster, M. B. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.04.006 · Cited by 3
Study design considerations for a large simple trial of bisphosphonates
Wright, N. C., Warriner, A. H., & Saag, K. G. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328362062b · Cited by 3
Self-citationGlucocorticoid-induced osteoporosis: how best to avoid fractures
Cooper, M. S. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310368737 · Cited by 3
The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?
Ruiz, C., Abril, N., Tarín, J. J., García‐Pérez, M. Á., & Cano, A. (2009) · Climacteric · doi:10.1080/13697130902736939 · Cited by 3
Saag, K. G., Curtis, J. R., & Warriner, A. H. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.130980 · Cited by 3
Self-citationNew Therapies for Osteoporosis
Hegge, K. A., Fornoff, A., Gutierres, S. L., & Haack, S. L. (2008) · Journal of Pharmacy Practice · doi:10.1177/0897190008322247 · Cited by 6
The Role of the Immune System in the Development of Osteoporosis and Fracture Risk
Geusens, P., Goldring, S. R., Briot, K., & Roux, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00011-6 · Cited by 3
Román, M., de Prado, A., & de Tembleque, F. R. (2015) · JBJS Case Connector · doi:10.2106/jbjs.cc.n.00153 · Cited by 4
Niimi, R., Kono, T., Nishihara, A., Hasegawa, M., Kono, T., & Sudo, A. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0151-5 · Cited by 3
Arthritis Accompanying Endocrine and Metabolic Disorders
Chakravarty, S. D., & Markenson, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00122-4 · Cited by 3
An Endocrinologist's Perspective
Lebovitz, H. E. (2013) · Cited by 3
Deal, C. L., & Abelson, A. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00201-1 · Cited by 3
Parathyroid hormone and abaloparatide treatment for osteoporosis
Cosman, F. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.02.005 · Cited by 4
Lane, N. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00101-8 · Cited by 3
Jiang, M., Liu, L., Xiang, X., Liang, R., Qin, X., Zhao, J., & Wei, Q. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13441 · Cited by 3
RetractedA Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis
Jamshidi, A., Gharibdoost, F., Sedighi, S., Hajiabbasi, A., Salari, A., Khabbazi, A., Mottaghi, P., Roudsari, A. T., Aghaei, M., Masooleh, I. S., et al. (2021) · Journal of Osteoporosis · doi:10.1155/2021/7584308 · Cited by 3
Nanki, T., Kawazoe, M., Uno, K., Hirose, W., Dobashi, H., Kataoka, H., Mimura, T., Hagino, H., & Kono, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010292 · Cited by 4
Osteoporosis en la mujer premenopáusica
Peris, P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.106940 · Cited by 4
Bai, Y., Chen, Q., Wang, R., & Huang, R. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1349351 · Cited by 2
Prolonged hypercalcemia induced by teriparatide: a case report and literature review
Lin, J., Tjokrosaputro, P. P., Ang, B. H., Chew, C. K., & Xu, C. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07569-z · Cited by 2
Nachsorge von Erwachsenen nach Lungentransplantation
Gottlieb, J., Wald, A., Bucher, B., Tapp, B., Hirsch, C., Schneider, C., Taube, C., Winter, H., Wilkens, H., Geldmacher, H., et al. (2026) · Pneumologie · doi:10.1055/a-2817-1499 · Cited by 2
Cassez, R., Cortet, B., Bouvard, B., Theis, D., Potey, C., Manier, S., Paccou, J., & Philippoteaux, C. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01693-x · Cited by 2
Gottlieb, J., Wald, A., Bucher, B., Tapp, B., Hirsch, C., Schneider, C. M., Winter, H., Wilkens, H., Geldmacher, H., Hettich, I. M., et al. (2026) · Respiration · doi:10.1159/000553086 · Cited by 2
Pillai, L., Bitto, A., Burnett, B. P., Polito, F., Levy, R. M., Stefano, V. D., Armbruster, M. A., Marini, H. R., Irrera, N., Altavilla, D., et al. (2010) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.01.014 · Cited by 2
Basic of Osteoporosis and the Topics
Kawaguchi, H. (2015) · Spinal Surgery · doi:10.2531/spinalsurg.29.259 · Cited by 2
Management of Established Rheumatoid Arthritis
Feely, M. G., & Mikuls, T. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-9993-2.00003-5 · Cited by 2
Glucocorticoid-induced osteoporosis in systemic lupus erythematosus
Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018) · Rheumatology Practice and Research · doi:10.1177/2059902118802510 · Cited by 3
Skripnikova, I. A., Косматова, О. В., Kolchina, М. А., Myagkova, M. A., & Alikhanova, N. A. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-3-359-367 · Cited by 3
Parathyroid Hormone Treatment for Osteoporosis
Cosman, F., & Lindsay, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00085-6 · Cited by 2
Seong, I., & Jeon, I. (2021) · Korean Journal of Neurotrauma · doi:10.13004/kjnt.2021.17.e8 · Cited by 2
Sato, A. Y., Cregor, M. D., McAndrews, K., Schurman, C. A., Schaible, E. G., Shutter, J. A., Vyas, P. K., Adhikari, B., Willis, M. S., Boerma, M., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.182664 · Cited by 4
Dhiman, V., Bhadada, S. K., Kanta, P., Kaur, G., Bhat, S., Bal, A., Sachdeva, N. K., Bhansali, A., Dhawan, D. K., Barnwal, R. P., et al. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_582_23 · Cited by 2
Development of Novel Biologically Active Compounds Based on Synthetic Organic Chemistry
Yakushiji, F. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00196 · Cited by 2
Glucocorticoid-induced osteoporosis
McDermott, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00018-8 · Cited by 2
Glucocorticoids and osteoporosis: predicting fracture risk
Cohen, S. B. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.194 · Cited by 2
Brown, S. (2009) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2009.10872192 · Cited by 2
Munno, O. D., & Sedie, A. D. (2011) · Reumatismo · doi:10.4081/reumatismo.2011.67 · Cited by 2
Osteoporosis secundaria a fármacos
Sallés, M., & Gelman, S. M. (2009) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2009.09.002 · Cited by 7
Wang, W., Tang, W., Yan, M., He, K., Yang, L., Jiang, L., Xiang, H., Yin, L., Sun, M., & Li, H. (2009) · Protein Expression and Purification · doi:10.1016/j.pep.2009.08.003 · Cited by 2
Hipercortisolismo de origen suprarrenal: s?ndrome de Cushing
García, J. M. M. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73189-8 · Cited by 4
Evaluation and Management of Osteoporosis and Fragility Fractures in The Elderly
Rosenzweig, A. B., & Mishra, R. (2009) · Aging Health · doi:10.2217/ahe.09.58 · Cited by 2
Selecting the optimal treatment for glucocorticoid-induced osteoporosis
Chopin, F., Hoppé, E., Morel, G., Biver, E., Borg, S., & Thomas, T. (2011) · Joint Bone Spine · doi:10.1016/s1297-319x(11)70009-4 · Cited by 2
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Berney, S. M. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79108-9 · Cited by 2
Management of glucocorticoid-induced osteoporosis: Lessons for clinical practice
Roux, C., Rajzbaum, G., Morel, G., Legrand, É., Laroche, M., Hoppé, E., Chopin, F., Borg, S., Biver, E., Cortet, B., et al. (2011) · Joint Bone Spine · doi:10.1016/s1297-319x(11)70010-0 · Cited by 2
Autosomal dominant hypocalcaemia due to a novel CASR mutation: clinical and genetic implications
Gagliardi, L., Burt, M. G., Feng, J., Poplawski, N. K., & Scott, H. S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13104 · Cited by 2
Massive Preperitoneal Hematoma after a Subcutaneous Injection
Katagiri, H., Yoshikawa, K., Lefor, A. K., Kubota, T., & Mizokami, K. (2016) · Case Reports in Surgery · doi:10.1155/2016/7013708 · Cited by 2
Thorsteinsson, A., Hansen, L., Vestergaard, P., & Eiken, P. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0444-6 · Cited by 2
Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update
Orjuela, A. M., Olarte, Ó. R., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., González, A. R., Lozano, A. T., Talero, A. P., Rueda, C., et al. (2018) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.01.004 · Cited by 6
PTH and PTHrP Analogs: Treatment of Osteoporosis
Tabacco, G., & Bilezikian, J. P. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_17 · Cited by 4
Glucocorticoid-induced osteoporosis
Lau, A. N., Sambrook, P. N., & Adachi, J. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00202-3 · Cited by 2
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Osteoporose induzida por glicocorticoides
da Silva, A. R. B., & Szejnfeld, V. L. (2019) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2019.18.2.44-50 · Cited by 2
Shinoda, K., & Taki, H. (2021) · Journal of Osteoporosis · doi:10.1155/2021/5515653 · Cited by 3
Systemic glucocorticoids in rheumatology
Saag, K. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00051-8 · Cited by 3
Self-citationBrance, M. L., Larroudé, M. S., Somma, L. F., Giacoia, E., Diehl, M., Galich, A. M., Stieben, L. A. R., Maher, M. C., Vega, M. D. L., Ringer, A., et al. (2023) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2022.10.002 · Cited by 2
Chalem, M., Casas, N., Domínguez, A. M., Fernández, D. G., González, A., Jauregui, E. A., Molina, J. F., Rincón, D. N., Gutiérrez, C. E. T., Grajales, F. J. V., et al. (2024) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2024.07.005 · Cited by 3
Le, Z., Yang, X., & Zhang, Y. (2021) · Surgical Science · doi:10.4236/ss.2021.126018 · Cited by 2
Slobodyan, O. M., Lavriv, L. P., Lopushniak, L. Y., Бамбуляк, А. В., & Boychuk, O. M. (2018) · Clinical anatomy and operative surgery · doi:10.24061/1727-0847.17.3.2018.14 · Cited by 2
Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 2)
Oelzner, P., Eidner, T., & Pfeil, A. (2022) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01128-7 · Cited by 2
Bahat, G., Ilhan, B., & Karan, M. A. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00752-3 · Cited by 2
Gan, D., Qin, L., & Xiao, G. (2026) · Research · doi:10.34133/research.1319 · Cited by 1
Is teriparatide or alendronate the best treatment for glucocorticoid-induced osteoporosis?
Woolf, A. D., & Åkesson, K. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0769 · Cited by 1
Osteoporosis and Rheumatoid Arthritis-Diagnosis, Diagnostics and Therapy
Buehring, B., Thomasius, F. E., Schultz, K., & Maus, U. M. (2021) · Osteologie/Osteology · doi:10.1055/a-1648-4414 · Cited by 1
Drugs against osteoporosis in perimenopausal and postmenopausal women
Lv, H., Zhang, Y., Li, J., Jia, Q., Yu, Y., Tang, H., Chen, W., Yang, Y. S., Jiang, Q., & Chen, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1682333 · Cited by 1
Yukishima, T., Kobayakawa, T., Hirano, Y., Kanayama, Y., Niimi, R., Etani, Y., Noguchi, T., Shimoyama, K., Maekawa, Y., Nakata, K., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag082 · Cited by 2
Kapszewicz, M., Michalska, M., & Sewerynek, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072488 · Cited by 2
Wu, Z., Han, L., Zhang, J.-X., Lin, Y.-Z., Fang, X., Guo, Y.-F., Jin, C., Guo, X., & Chen, L. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116601 · Cited by 3
EndoBridge 2025: pearls and highlights
Yıldız, B. O., Armenti, M., Brandi, M. L., Carey, J., Carling, T., Ciudin, A., Dhatariya, K., Fountas, A., Frühbeck, G., Goulis, D. G., et al. (2026) · HORMONES · doi:10.1007/s42000-026-00804-0 · Cited by 1
Longitudinal osteoporosis therapy: treat-to-target and sequential strategies—a narrative review
Tskhakaia, I., & Danila, M. I. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261466911 · Cited by 1
for the Hellenic ExFOS study group, Aloumanis, K., Kapetanos, G. A., Bartzis, N., & Drossinos, V. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0600-8 · Cited by 2
Romosozumab/CDP7851 for the treatment of osteoporosis
Sim, I., & Ebeling, P. R. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1079482 · Cited by 1
How effective is risedronate in preventing bone loss in patients on high-dose steroids?
Arabi, A., & Fuleihan, G. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0923 · Cited by 1
Nogués, X. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70174-8 · Cited by 1
Metadata
- Authors
- Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R.
- Affiliations
- University of Alabama at Birmingham (US)
- Columbia University (US)
- KU Leuven (BE)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2028-2039
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042007405
- Cited by
- 914
- References
- 40
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 36 · 2023: 32 · 2022: 45 · 2021: 56 · 2020: 43 · 2019: 38 · 2018: 53 · 2017: 35 · 2016: 33 · 2015: 51 · 2014: 49 · 2013: 59 · 2012: 61
- FWCI
- 63.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- teriparatide, alendronate, glucocorticoid-induced osteoporosis, bisphosphonates, bone mineral density, vertebral fractures, non-vertebral fractures, fracture risk, serum calcium, bone turnover markers, anabolic therapy
- MeSH terms
- Aged, Aged, 80 and over, Calcium, Double-Blind Method, Female, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Risk, Biomarkers, Bone Density, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.